Image Ben Hargreaves R&D Taking an ‘upside-down’ approach to mRNA delivery Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full poten Patients The rise of prescription drug abuse and drug diversion As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased. Healthcare The end-of-life care conundrum Research advises against aggressive cancer treatment at the end-of-life stages of the disease. Cancer Targeting the ecosystem to make cancer extinct The ICR and The Royal Marsden have embarked on an ambitious research collaboration to disrupt the cancer cell ecosystem. Load more results
R&D Taking an ‘upside-down’ approach to mRNA delivery Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full poten
Patients The rise of prescription drug abuse and drug diversion As prescription drug abuse has grown in the US and Europe, the diversion of such treatments from legitimate sources has also increased.
Healthcare The end-of-life care conundrum Research advises against aggressive cancer treatment at the end-of-life stages of the disease.
Cancer Targeting the ecosystem to make cancer extinct The ICR and The Royal Marsden have embarked on an ambitious research collaboration to disrupt the cancer cell ecosystem.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
